Literature DB >> 11546936

CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progression.

J Reynes1, P Portales, M Segondy, V Baillat, P André, O Avinens, M C Picot, J Clot, J F Eliaou, P Corbeau.   

Abstract

OBJECTIVE AND
DESIGN: We have recently shown that the number of CCR5 molecules at the surface of peripheral blood CD4 T cells (CCR5 density) correlates with the viral RNA plasma level in HIV-1-infected individuals. As viral load is a strong predictor of outcome in HIV infection, the present study examines the correlation between CCR5 density and HIV-1 disease progression.
METHODS: Using a quantitative flow cytometry assay, we measured CCR5 density in HIV-1-infected adults and control healthy volunteers. The CCR5 genotype (presence of a Delta 32 allele) was also determined.
RESULTS: CCR5 density was stable over time on non-activated, HLA-DR(-)CD4 T cells of infected individuals. In a study cohort of 25 patients, asymptomatic and non-treated, we observed a correlation between CCR5 density on HLA-DR(-)CD4 T cells and the CD4 T cell slope (P = 0.026), which was independent of the presence or absence of the Delta 32CCR5 deletion. In particular, slow progressors expressed lower CCR5 densities than non-slow progressors (P = 0.004) and non-infected control subjects (P = 0.002).
CONCLUSION: These results are compatible with the hypothesis that CCR5 density, which is a key factor of HIV-1 infectability, determines in-vivo HIV production, and thereby the rate of CD4 cell decline. Consequently, CCR5 density quantitation could be a new valuable prognostic tool in HIV-1 infection. Moreover, these data emphasize the therapeutic potential of treatments that reduce functional CCR5 density.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11546936     DOI: 10.1097/00002030-200109070-00004

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  39 in total

1.  CCR5 deficiency mitigates the deleterious effects of tumor necrosis factor α antagonism in murine histoplasmosis.

Authors:  Danielle N Kroetz; George S Deepe
Journal:  J Infect Dis       Date:  2012-01-23       Impact factor: 5.226

2.  The effects of early syphilis on CD4 counts and HIV-1 RNA viral loads in blood and semen.

Authors:  S T Sadiq; J McSorley; A J Copas; J Bennett; S J Edwards; S Kaye; S Kirk; P French; I V D Weller
Journal:  Sex Transm Infect       Date:  2005-10       Impact factor: 3.519

3.  The strength of the chemotactic response to a CCR5 binding chemokine is determined by the level of cell surface CCR5 density.

Authors:  Caroline Desmetz; Yea-Lih Lin; Clément Mettling; Pierre Portalès; Herisoa Rabesandratana; Jacques Clot; Pierre Corbeau
Journal:  Immunology       Date:  2006-12       Impact factor: 7.397

4.  CCR5 expression is reduced in lymph nodes of HIV type 1-infected women, compared with men, but does not mediate sex-based differences in viral loads.

Authors:  Amie L Meditz; Joy M Folkvord; Ngan H Lyle; Kristina Searls; Yolanda S Lie; Eoin P Coakley; Martin McCarter; Samantha Mawhinney; Elizabeth Connick
Journal:  J Infect Dis       Date:  2013-10-31       Impact factor: 5.226

5.  HLA-DR+ CD38+ CD4+ T lymphocytes have elevated CCR5 expression and produce the majority of R5-tropic HIV-1 RNA in vivo.

Authors:  Amie L Meditz; Michelle K Haas; Joy M Folkvord; Kelsey Melander; Russ Young; Martin McCarter; Samantha Mawhinney; Thomas B Campbell; Yolanda Lie; Eoin Coakley; David N Levy; Elizabeth Connick
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

6.  Double-edged genetic swords and immunity: lesson from CCR5 and beyond.

Authors:  Sunil K Ahuja; Weijing He
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

7.  Association between HIV-1 tropism and CCR5 human haplotype E in a Caucasian population.

Authors:  Kristi Huik; Radko Avi; Helen Uibopuu; Merit Pauskar; Tõnu Margus; Tõnis Karki; Tõnu Krispin; Piret Kool; Kristi Rüütel; Ave Talu; Katri Abel-Ollo; Anneli Uusküla; Andrew Carrillo; Weijing He; Sunil K Ahuja; Irja Lutsar
Journal:  J Acquir Immune Defic Syndr       Date:  2014-07-01       Impact factor: 3.731

8.  Inhibition of human immunodeficiency virus (HIV-1) infection in human peripheral blood leucocytes-SCID reconstituted mice by rapamycin.

Authors:  F Nicoletti; C Lapenta; C Lamenta; S Donati; M Spada; A Ranazzi; B Cacopardo; K Mangano; F Belardelli; C Perno; S Aquaro
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

9.  Efficient mucosal transmissibility but limited pathogenicity of R5 SHIV SF162P3N in Chinese-origin rhesus macaques.

Authors:  Alexandra Mumbauer; Agegenhu Gettie; James Blanchard; Cecilia Cheng-Mayer
Journal:  J Acquir Immune Defic Syndr       Date:  2013-04-15       Impact factor: 3.731

10.  Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro.

Authors:  Alonso Heredia; Bruce Gilliam; Olga Latinovic; Nhut Le; Douty Bamba; Anthony Devico; Gregory B Melikyan; Robert C Gallo; Robert R Redfield
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.